Home » Cardiovascular » ATTR-ACT Trial (2018): Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.

ATTR-ACT Trial (2018): Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.